Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunosuppressive agents in dermatology

V C Ho1, D M Zloty

  • 1Division of Dermatology, University of British Columbia, Vancouver, Canada.

Dermatologic Clinics
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Common Skin Cancers: How to diagnose and treat them.

Canadian family physician Medecin de famille canadien·2011
Same author

A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.

The British journal of dermatology·2007
Same author

Update on the use of ciclosporin in immune-mediated dermatoses.

The British journal of dermatology·2006
Same author

Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial.

The British journal of dermatology·2005
Same author

The use of ciclosporin in psoriasis: a clinical review.

The British journal of dermatology·2004
Same author

Ciclosporin in psoriasis clinical practice: an international consensus statement.

The British journal of dermatology·2004
Same journal

The Evidence Is In: Devices and Biologics Reshaping Modern Dermatology.

Dermatologic clinics·2026
Same journal

Energy-Based Devices for Body Contouring.

Dermatologic clinics·2026
Same journal

Microfocused Ultrasound with Visualization for Skin Tightening: Clinical Applications, Safety, and Technical Considerations.

Dermatologic clinics·2026
Same journal

Devices in Onychomycosis: A Status Update.

Dermatologic clinics·2026
Same journal

Acne Laser Devices in Dermatology.

Dermatologic clinics·2026
Same journal

Fractional Laser Therapy for Androgenetic Alopecia: Mechanisms, Clinical Evidence, and Practical Implementation.

Dermatologic clinics·2026
See all related articles

Azathioprine, cyclophosphamide, and cyclosporine are immunosuppressive drugs used in dermatology. Azathioprine is preferred for milder conditions, while cyclophosphamide is more effective for severe diseases despite higher toxicity.

Area of Science:

  • Dermatology
  • Immunosuppressive Therapy

Background:

  • Immunosuppressive agents are crucial in managing various dermatological conditions.
  • Azathioprine, cyclophosphamide, and cyclosporine are frequently employed by dermatologists.

Purpose of the Study:

  • To review the indications, efficacy, and safety profiles of azathioprine, cyclophosphamide, and cyclosporine in dermatology.
  • To guide dermatologists in judiciously selecting and monitoring immunosuppressive agents.

Main Methods:

  • Literature review of immunosuppressive agents used in dermatology.
  • Analysis of clinical applications, efficacy, and safety data for azathioprine, cyclophosphamide, and cyclosporine.

Main Results:

  • Azathioprine is favored for bullous pemphigoid, cutaneous vasculitides, chronic eczematous dermatitides, and connective tissue diseases due to its safety.

Related Experiment Videos

  • Cyclophosphamide is more effective for severe conditions like Wegener's granulomatosis and pemphigus, despite increased toxicity.
  • Cyclosporine shows promise in psoriasis, lichen planus, pyoderma gangrenosum, and chronic eczematous dermatitides, but long-term safety requires further evaluation.

    • Conclusions:

    • The choice of immunosuppressive agent depends on disease severity and the agent's risk-benefit profile.
    • Dermatologists must be well-versed in the indications, side effects, dosage, and monitoring of these potent medications.